Extracorporeal Membrane Oxygenation (ECMO) Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030

Extracorporeal Membrane Oxygenation (Ecmo) Devices Market By Machine Modality (Veno-Arterial, Veno-Venous, And Arterio-Venous), By Patient Type (Pediatric And Adult), By Application (Respiratory, Cardiac, And Others), and geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing incidence of cardiopulmonary disease and respiratory failure and the growing demand of portable ecmo devices across the globe.

The global extracorporeal membrane oxygenation (ECMO) devices market is estimated to grow at a CAGR of 4.1% during the forecast period from 2023 to 2028. The demand for extracorporeal membrane oxygenation (ECMO) devices is being boosted by the growing need for long-term circulatory support in chronic respiratory and cardiac disorders, rising technological advancements leading to improved patient outcomes, increasing adoption of extracorporeal membrane oxygenation machines, introduction of emerging technologies by key players to eliminate potential challenges during the process, rising adoption unhealthy habits, large patient pool suffering from lung and heart diseases, rising product launches and approvals, among others are thereby contributing to the overall growth of the extracorporeal membrane oxygenation (ECMO) devices market during the forecast period from 2023-2028.

Extracorporeal Membrane Oxygenation (ECMO) Devices Market Dynamics:

The extracorporeal membrane oxygenation (ECMO) devices market is witnessing a growth in product demand owing to various factors, one of the key factors being the increasing incidence of heart and respiratory disease.

ECMO systems are used for long-term respiratory or cardiopulmonary failure and provide assisted extracorporeal circulation and physiologic gas exchange of the patient's blood for more than six hours.

Ischemic heart disease (IHD), also referred to as coronary artery disease (CAD) and atherosclerotic cardiovascular disease (ACD) is a leading cause of death worldwide. According to the Global Epidemiology of Ischemic Heart Disease study (2020), every year, globally, IHD affects around 126 million individuals (1,655 per 100,000), which is approximately 1.72% of the world's population. These patients require artificial support during cardiovascular surgery driving the demand for ECMO market.

Further, as per the data from the British Heart Foundation 2023, around 620 million people were living with heart and circulatory diseases across the world, in 2022. According to World Health Organization (WHO) 2021, approximately 17.9 million people died from cardiovascular diseases, which is an estimated 31% of all deaths worldwide in 2021. By 2030, around 23.6 million people are expected to die due to cardiovascular disorders.

As per the data of the World Health Organization (2021), about 65 million people suffer from chronic obstructive pulmonary disease (COPD) and 3 million die from it each year, making it the third leading cause of death worldwide. A long-term, effective ECMO solution gives critically-ill patients the time and support needed to heal, driving the demand for the extracorporeal membrane oxygenation machine in patients of all ages.

Further, in 2021, more than 33,000 children patients got ECMO support worldwide, according to the latest data available from Extracorporeal Life Support Organization (ELSO) registry. Also, the number of hospitals offering ECMO services reached 264 in 2019 up from 108 in 2008. The usage of ECMO machines has become more widespread over time. ECMO machines were formerly solely used in cases of circulatory or respiratory failure, but now they are also used in cases of heart failure, sepsis, and post-organ transplantation.

Therefore, the above-mentioned factors are contributing to the growth of the extracorporeal membrane oxygenation (ECMO) devices market during the forecast period from 2023-2028.

However, complications associated with ECMO machines, such as infections, technical failure, bleeding, stringent regulatory approvals about the device, and others may restrict the extracorporeal membrane oxygenation (ECMO) devices market growth.

Extracorporeal Membrane Oxygenation (ECMO) Devices Market Segment Analysis:

Extracorporeal Membrane Oxygenation (ECMO) Devices Market by Machine Modality (Veno-Arterial, Veno-Venous, and Arterio-Venous), Patient Type (Pediatric and Adult), Application (Respiratory, Cardiac, and Others), and Geography (North America, Europe, Asia-Pacific, and the Rest of the World application segment of the extracorporeal membrane oxygenation (ECMO) devices market, the respiratory category is expected to amass a significant revenue share in the year 2022. This can be attributed to the high prevalence of respiratory disease driving the demand for ECMO for the treatment or management of respiratory diseases.

Asthma is one of the major non-communicable diseases. It is a chronic disease of the air passages of the lungs which inflames and narrows them. According to a World Health Organization (WHO) 2021 report, approximately 262 million people in 2019 were suffering from asthma globally. Annually, it has been estimated that 15 million disability-adjusted life-years are lost and 250,000 asthma deaths are reported worldwide.

According to the Extracorporeal Life Support Organization (ELSO), the technique was used to save up to half of the seriously ill Covid-19 patients for whom ventilation isn't working. It was noticed that 55% of the Covid-19 patients who had been placed on ECMO had subsequently survived the condition of patients for whom no other treatment was working.

The great majority of COVID-19 patients needing ECMO were supported using veno-venous (V-V) ECMO for acute respiratory distress syndrome (ARDS).

Further, in November 2022, LivaNova PLC received 510(k) clearance for extracorporeal membrane oxygenation (ECMO) from the U.S. Food and Drug Administration (FDA) for LifeSPARC™, the Company's next-generation Advanced Circulatory Support (ACS) pump and controller system. It is intended for use in adult patients with acute respiratory failure.

Thus, the above-mentioned factors are likely to propel the demand for the respiratory segment, thereby contributing to the growth of the extracorporeal membrane oxygenation (ECMO) devices market during the forecast period from 2023-2028.

North America is expected to dominate the overall Extracorporeal Membrane Oxygenation (ECMO) Devices Market:

Among all the regions, North America is estimated to account for the largest share in the extracorporeal membrane oxygenation (ECMO) devices market in the year 2022. This domination is due to the growing prevalence of cardiovascular and pulmonary diseases, the growing geriatric population, the introduction of many products, and others in the region.

COVID-19 also boosted the demand for compact cardiopulmonary bypass systems and in October 2020, Abiomed announced that its compact cardiopulmonary bypass system, Breethe OXY-1, received 510(k) clearance from the FDA. This launch boosted the ECMO market in the US and help the company to gain market share.

Further, according to the Centers for Disease Control and Prevention (CDC) 2022, more than 795,000 people in the United States suffer from a stroke every year. As per the same source, approximately 200,000 coronary artery bypass graft surgeries take place each year in the US and are the most commonly performed cardiac procedure. Henceforth, treatment requires extracorporeal membrane oxygenation machines, such as heart-lung machines and oxygenators.

Further, in October 2020, the U.S. Food and Drug Administration (FDA) granted 510(k) clearance to Abiomed for an all-in-one, compact extracorporeal membrane oxygenation (ECMO) cardiopulmonary bypass system called the Abiomed Breethe OXY-1 System.

Thus, all the above-mentioned factors will lead to an increase in the North America extracorporeal membrane oxygenation (ECMO) devices market growth during the forecasting period of 2023-2028.

Extracorporeal Membrane Oxygenation (ECMO) Devices Market Key Players:

Some of the key market players operating in the extracorporeal membrane oxygenation (ECMO) devices market include Getinge Group, Medtronic, LivaNova PLC, XENIOS AG, Terumo Corporation, MicroPort Scientific Corporation, NIPRO Corporation, OriGen Biomedical, Inc., EUROSETS S.r.l., ALung Technologies, Inc., Medos Medizintechnik AG, Abiomed, Novalung, Senko Medical Instrument Manufacturing Co. Ltd., Braile Biomedica Ltd., Sorin, Thoratec Corporation, MAQUET Holding B.V. & Co. KG., Tianjin Medical, SHANDONG WEGO NEW LIFE MEDICAL DEVICES CO., LTD., and others.

Recent Developmental Activities in the Extracorporeal Membrane Oxygenation (ECMO) Devices Market:

• In August 2022, AirECMO, Inc., a division of Keystone Perfusion Services, announced a strategic partnership with industry-leading air ambulance provider, REVA, to provide ECMO transportation capabilities globally.
• In July 2022, Inspira™ Technologies launched the Liby System, an advanced form of life support better known by the medical industry as extracorporeal membrane oxygenation (ECMO), used to treat patients with life-threatening heart and lung failure.
• In April 2020, the U.S. Food and Drug Administration (FDA) issued guidance to provide a policy to help expand the availability of devices used in extracorporeal membrane oxygenation (ECMO) therapy to address the novel coronavirus (COVID-19, SARS-CoV-2) public health emergency.
• In April 2020, Abiomed acquired Breethe, the developer of a novel extracorporeal membrane oxygenation (ECMO) system that will complement and expand Abiomed's product portfolio to more comprehensively serve the needs of patients whose lungs can no longer provide sufficient oxygenation, including patients suffering from cardiogenic shock or respiratory failure such as due to ARDS, H1N1, SARS, or COVID-19.

Key Takeaways from the Extracorporeal Membrane Oxygenation (ECMO) Devices Market Report Study

• Market size analysis for current extracorporeal membrane oxygenation (ECMO) devices market size (2022), and market forecast for 5 years (2023-2028)
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global extracorporeal membrane oxygenation (ECMO) devices market.
• Various opportunities available for the other competitor in the extracorporeal membrane oxygenation (ECMO) devices market space.
• What are the top-performing segments in 2022? How these segments will perform in 2028.
• Which are the top-performing regions and countries in the current extracorporeal membrane oxygenation (ECMO) devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for extracorporeal membrane oxygenation (ECMO) devices market growth in the coming future?

Target Audience who can be benefited from this Extracorporeal Membrane Oxygenation (ECMO) Devices Market Report Study

• Extracorporeal membrane oxygenation (ECMO) device product providers
• Research organizations and consulting companies
• Extracorporeal membrane oxygenation (ECMO) devices-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in extracorporeal membrane oxygenation (ECMO) devices
• Various End-users who want to know more about the extracorporeal membrane oxygenation (ECMO) devices market and the latest technological developments in the extracorporeal membrane oxygenation (ECMO) devices market.

Frequently Asked Questions for the Extracorporeal Membrane Oxygenation (ECMO) Devices Market:

1. What are extracorporeal membrane oxygenation (ECMO) devices?

Extracorporeal membrane oxygenation (ECMO), also known as extracorporeal life support (ECLS), is an extracorporeal technique of providing prolonged cardiac and respiratory support to persons whose heart and lungs are unable to provide an adequate amount of gas exchange or perfusion to sustain life.

2. What is the market for global extracorporeal membrane oxygenation (ECMO) devices?

The global extracorporeal membrane oxygenation (ECMO) devices market is estimated to grow at a CAGR of 4.1% during the forecast period from 2023 to 2028.

3. What are the drivers for the global extracorporeal membrane oxygenation (ECMO) devices market?

The demand for extracorporeal membrane oxygenation (ECMO) devices is primarily being heightened by the rising incidence of cardiopulmonary disease and respiratory failure, increasing adoption rate of extracorporeal membrane oxygenation machine (ECMO), increasing number of hospitals offering ECMO services, increasing geriatric population base, and rising number of awareness programs among others, thereby contribute to the overall growth of the extracorporeal membrane oxygenation (ECMO) devices market during the forecast period from 2023-2028.

4. Who are the key players operating in the global extracorporeal membrane oxygenation (ECMO) devices market?

Some of the key market players operating in the extracorporeal membrane oxygenation (ECMO) devices market include Getinge Group, Medtronic, LivaNova PLC, XENIOS AG, Terumo Corporation, MicroPort Scientific Corporation, NIPRO Corporation, OriGen Biomedical, Inc., EUROSETS S.r.l., ALung Technologies, Inc., Medos Medizintechnik AG, Abiomed, Novalung, Senko Medical Instrument Manufacturing Co. Ltd., Braile Biomedica Ltd., Sorin, Thoratec Corporation, MAQUET Holding B.V. & Co. KG., Tianjin Medical, SHANDONG WEGO NEW LIFE MEDICAL DEVICES CO., LTD., and others.

5. Which region has the highest share in the extracorporeal membrane oxygenation (ECMO) devices market?

North America is expected to dominate the overall extracorporeal membrane oxygenation (ECMO) devices market during the forecast period from 2023-2028. Factors such as the increasing prevalence of cardiovascular and respiratory diseases, technological advancements in ECMO technology, increased adoption of ECMO systems, government support for quality healthcare, high purchasing power parity, and adoption of advanced technologies of extracorporeal membrane oxygenation (ECMO) devices among others will positively impact the North American extracorporeal membrane oxygenation (ECMO) devices market.


This product will be delivered within 2 business days.